News | March 04, 2024
Govt. setting up of Ayush - ICMR Advanced Centre for AI-ACIHR at select AIIMS
Launch of Indian public health standards for Ayush healthcare facilities
Launch of Indian public health standards for Ayush healthcare facilities
PLI scheme envisages manufacturing of 41 Bulk Drugs with a total outlay of Rs. 6,940 cr. during the tenure of the scheme from 2020-21 to 2029-30
EDQM conducts GMP inspection of SMS Pharmaceuticals’ API facility
Clinical findings support the safety and efficacy of BMND08 at a maximum dosage of 12mg
The product will be launched in March 2024
The production started from its greenfield manufacturing facility at Aurangabad in Maharashtra
_256_384.jpg)
The overall transaction is expected to conclude over next 12-15 months subject to receipt of all relevant shareholder and regulatory approvals
_in_Mizushima,_Japan_256_384.jpg)
Contributing to lower risk of potentially carcinogenic nitrosamine impurities in pharmaceuticals
The U.S. FDA recently approved Xolair as the first and only medicine for children and adults with one or more food allergies
Survodutide has potential to become best-in-class treatment for metabolic dysfunction-associated steatohepatitis
Subscribe To Our Newsletter & Stay Updated
